

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Class 3 semaphorins in cardiovascular development

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1593768> since 2017-05-14T23:05:26Z

Published version:

DOI:10.1080/19336918.2016.1212805

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

Class 3 semaphorins in cardiovascular development

Donatella Valdembri, Donatella Regano, Federica Maione, Enrico Giraud, and Guido Serini

QUERY SHEET

This page lists questions we have about your paper. The numbers displayed at left can be found in the text of the paper for reference. In addition, please review your paper as a whole for correctness.

- Q1.** Au: Please confirm you have submitted your publication costs form.
- Q2.** Au: Please provide keywords.
- Q3.** Au: Please provide full mailing address for correspondence.
- Q4.** Au: The volume and page numbers for References [31] have been inserted using data from CrossRef.
- Q5.** Au: The page numbers for References [31] have been inserted using data from CrossRef.

TABLE OF CONTENTS LISTING

The table of contents for the journal will list your paper exactly as it appears below:

Class 3 semaphorins in cardiovascular development

Donatella Valdembri, Donatella Regano, Federica Maione, Enrico Giraud, and Guido Serini

REVIEW

Q1

Class 3 semaphorins in cardiovascular development

Donatella Valdembrì^{a,b}, Donatella Regano^{c,d}, Federica Maione^{c,d}, Enrico Giraudo^{c,d}, and Guido Serini^{a,b}

^aDepartment of Oncology, University of Torino School of Medicine, Candiolo, Torino, Italy; ^bLaboratory of Cell Adhesion Dynamics, Candiolo Cancer Institute - Fondazione del Piemonte per l'Oncologia (FPO) Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Candiolo, Torino, Italy; ^cLaboratory of Transgenic Mouse Models, Candiolo Cancer Institute - Fondazione del Piemonte per l'Oncologia (FPO) Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Candiolo, Torino, Italy; ^dDepartment of Science and Drug Technology, University of Torino, Candiolo, Torino, Italy

ABSTRACT

Secreted class 3 semaphorins (Sema3), which signal through holoreceptor complexes that are formed by different subunits, such as neuropilins (Nrps), proteoglycans, and plexins, were initially characterized as fundamental regulators of axon guidance during embryogenesis. Subsequently, Sema3A, Sema3C, Sema3D, and Sema3E were discovered to play crucial roles in cardiovascular development, mainly acting through Nrp1 and Plexin D1, which funnels the signal of multiple Sema3 in vascular endothelial cells. Mechanistically, Sema3 proteins control cardiovascular patterning through the enzymatic GTPase-activating-protein activity of the cytodomain of Plexin D1, which negatively regulates the function of Rap1, a small GTPase that is well-known for its ability to drive vascular morphogenesis and to elicit the conformational activation of integrin adhesion receptors.

ARTICLE HISTORY

Received 26 May 2016
Revised 7 July 2016
Accepted 11 July 2016

Q2

The complex morphogenetic events that lead to the development of cardiovascular system, which have been extensively described¹ and/or reviewed^{2,3} elsewhere, rely on the property of cells to differentiate, adhere to each other as well as to the surrounding extracellular matrix and migrate in response to guidance cues.^{2,3} Among the different molecules capable of regulating the directionality of cell motility, semaphorins (Semas) represent a large family of secreted or membrane-associated glycoproteins, conserved both structurally and functionally from viruses to mammals and able to provide repulsive or attractive signals to migrating cells.

Sema were originally identified as axon guidance molecules in the developing nervous system.^{4,5} Afterward, these molecules have been shown to regulate other physiological and pathological processes outside of the nervous system, such as vascular endothelial cell motility, cardiovascular development, lymphocyte activation, bone and lung morphogenesis, cancer angiogenesis and metastatic dissemination.^{3,6,7,8} The Sema family is divided into 8 classes accordingly to structural characteristics and organisms of origin: class 1 and 2 are encoded by invertebrates, classes 3–7 are from vertebrates, and class V Sema are found in viruses. The overall molecular architecture is quite different for the various Sema, being

characterized by class-specific structural domains. The only exception is the conserved 500 amino acid-long 7-blade β -propeller folded “sema” domain, located close to the N-terminus of the proteins and present in all family members.⁹ In vertebrates, class 3 Sema (Sema3) consists of 7 soluble molecules of ~100 kDa (designated by letters from A to G), which are produced as secreted proteins by cells of multiple lineages, including endothelial and epithelial cells, neurons, and specific tumor cells. In Sema3, the N-terminal sema domain is followed by a plexin-semaphorin-integrin (PSI) domain, an immunoglobulin (Ig)-like domain, and a C-terminal basic domain (Fig. 1).

The core components of the Sema3 holoreceptor complexes (Fig. 1) belong to the families of plexins and neuropilins (Nrps) (Table 1). Plexins are a wide family of transmembrane proteins categorized into 4 (A to D) classes on the basis of structural similarities. The extracellular portion of plexins consists of several different moieties, among which a central role is played by a divergent sema domain; their intracellular region contains instead a functionally crucial guanosine triphosphatase (GTPase)-activating protein (GAP) domain^{10–13} (Fig. 1). Different Sema crystals have been analyzed so far,^{14–18} indicating how all Semas are homodimers, in which, differently from sema domain containing plexins,

CONTACT Enrico Giraudo  enrico.giraudo@ircc.it

Color versions of one or more of the figures in the article can be found online at www.tandfonline.com/kcam.

© 2016 Taylor & Francis

Q3




Figure 1. Sema3A signaling *via* the Nrp1-Plexin A/D1 holoreceptor. From the N- to the C-terminus Sema3A displays a sema domain, a PSI domain, an Ig-like domain, and a basic domain. Nrp1 and type A or D plexins constitute the main components of the Sema3A holoreceptor. The extracellular domains of Nrp1 contain 2 complement binding domains (a1/a2), 2 coagulation factor V/VIII homology domains (b1/b2), and a MAM domain (c). The b1 domain of Nrp1 mediates its high affinity (*black double arrow*) binding of Nrp1 to the basic domain of Sema3A. The extracellular portion of plexins consists of a sema domain and a series of 3 PSI and 4 integrin-transcription factor-plexin (IPT) domains. The intracellular segment of plexins primarily comprises a GAP domain that exerts its enzymatic activity on Rap1, a small GTPase that, *via* effector proteins such as RIAM1, promotes the conformational activation of integrins through talin. The dimeric sema domains of Sema3A would interact at very low affinity (*gray double arrow*) with the sema domains of 2 monomeric type A/D plexins, thus promoting their dimerization (not shown) and the activation of their cytosolic Rap1 GAP enzymatic activity, finally resulting in integrin inactivation.

a ‘face-to-face’ interaction between the top surfaces of the sema domains occurs.⁹ If compared to membrane associated Semas, secreted Sema3 proteins display a less hydrophobic dimer interface that crucially need to be stabilized by disulphide bonds between Ig domains, which are negatively regulated by the proteolytic activity of furins.^{19,20} Crystal structures of several membrane associated Semas in complex with their cognate plexin receptors unveiled that electrostatic interactions mediate an head-to-head interaction between each sema domain of a Sema dimer and the sema domain of a monomeric plexin, giving rise to a 2:2 Sema-plexin heterotetramer.^{9,15-17} Functional studies provided evidence that the same head-to-head interface is likely employed by

Sema3A to bind to and signal through plexin receptors,¹⁷ nevertheless, since so far no physiological high affinity binding has been revealed between the sema domains of Sema3A and plexins,¹⁸ such a canonical binding between Sema3A and plexins must be extremely weak and need the essential involvement of co-receptors such as Nrp1¹⁸ or proteoglycans.^{21,22}

In vertebrates 2 Nrps are present (Nrp1 and Nrp2) that act as Sema3 co-receptors.²³ The extracellular domains of both Nrps contain 2 complement binding domains (a1/a2), 2 coagulation factor V/VIII homology domains (b1/b2), and a MAM domain (c), while the short cytoplasmic domain is about 40 amino acids long, and contains a C-terminal 3 amino acid-long (S-E-A) sequence that represents a PDZ-binding motif. In addition to Sema3, Nrp1 and Nrp2 also bind to vascular endothelial growth factor-A (VEGF-A) and -C (VEGF-C) family members respectively and function as their co-receptors.²³⁻²⁵ The b1 domain mediates the high affinity binding of Nrp1 to the basic domain of Sema3 proteins and VEGF-A.²⁶⁻³¹ While VEGF-A naturally displays a C-terminal arginine, a furin-dependent proteolytic processing of Sema3 must occur to allow the exposure of the Nrp1-binding C-terminal basic sequence.^{19,23,30-33} Accordingly, the C-terminal basic stretch peptides of furin-processed Sema3A or Sema3F inhibit effectively and dose-dependently the binding of VEGF-A to the b1

Table 1. Sema3 holoreceptor core components. Nrp co-receptors and plexin receptor that are crucial for transduction of signals elicited by the different Sema3 proteins either *in vivo* or *in vitro* are highlighted in bold.

| Semaphorin | Neuropilin | References | Plexin | References |
|------------|-------------------|------------|---------------------------|----------------|
| Sema3A | Nrp1 | 90,92,93 | Plexin A1, A2, A3, A4, D1 | 58-63,94,95 |
| Sema3B | Nrp1, Nrp2 | 79,96 | ? | |
| Sema3C | Nrp1, Nrp2 | 90,96,97 | Plexin A2, D1 | 59,63,81,97-99 |
| Sema3D | Nrp1 | 100,101 | ? | |
| Sema3E | Nrp1 | 99,102 | Plexin D1 | 64,99,103 |
| Sema3F | Nrp1, Nrp2 | 26,90 | Plexin A1, A2, A3 | 58-60,95 |
| Sema3G | Nrp1, Nrp2 | 91,104 | ? | |

domain of Nrp1.^{30,33} Furthermore, 3 independent studies
 105 proved that VEGF-A and *Sema3A* compete for binding
 Nrp1 on the cell surface and how this competition
 encompasses a binding site within Nrp1 b1 domain.³⁴⁻³⁶
 A surface plasmon resonance-based study did not detect
 any competition between *Sema3A* and VEGF-A for bind-
 110 ing to immobilized Nrp1-Fc³⁷; the reason(s) for discrep-
 ancies among the work by Appleton et al.³⁷ and the other
 3 studies³⁴⁻³⁶ are presently unclear, but they could be due,
 for example, to differences in furin-cleavage patterning of
Sema3A C-terminal basic stretch.^{19,33} Indeed, an-N-
 115 terminal disulphide-bonded helical region precedes the
 C-terminal basic stretch of *Sema3* proteins³³ and, while
 the C-terminal basic stretch of *Sema3F* has only one furin
 consensus site, *Sema3A* displays instead 3 furin cleavage
 sites whose processing is central for *Sema3A* regula-
 120 tion.^{19,33} In particular, shortening the distance between
 the helical region and the C-terminal motif results in a
 concomitant reduction of *Sema3A* affinity for Nrp1 b1
 domain³³ and biological activity.¹⁹ The recent finding
 that proteolytic processing is needed to expose the C-
 125 terminal arginine of VEGF-C that directly binds the
 Nrp2 b1 domain²⁵ suggests how the binding of Nrp
 ligands other than *Sema3* proteins might also be regulated
 by the protease-driven strategy. The a1 domain of Nrp1
 does not directly bind with high affinity the sema domain
 130 of *Sema3A*,¹⁸ but rather favors the coordination of the lat-
 ter with the sema domain of type A plexins, such as
 Plexin A2.^{9,18} All together, these data suggest a model in
 which, while the b1 domain of Nrp1 binds with high
 affinity to the basic domain of *Sema3A*, the a1 domain of
 135 Nrp1 help the sema domain of *Sema3A* to coordinate
 with sema domain of type A plexins and likely activate
 the signaling of the latter.^{9,18,38}

In this review, we summarize the current advances on
 the involvement of *Sema3* in cardiovascular development
 140 (Table 2).

Sema3A

In the developing zebrafish embryo, *Sema3A* is required
 for the proper patterning of trunk intersegmental blood
 vessels.^{39,40} Gene and/or genome duplication are mecha-
 145 nisms for functional improvement during evolution.⁴¹
 Compared to other vertebrate species, the zebrafish tele-
 ost ancestor underwent an additional round of whole-
 genome duplication.⁴¹ As a consequence, the zebrafish
 displays 2 *Sema3a* ortholog genes, *sema3a1* and *sema3a2*
 150 that are expressed in the developing somites.³⁹ Somite-
 derived *Sema3A1* and *Sema3A2* proteins restrain within
 the intersomitic boundaries the vascular sprouts that
 bud from trunk large blood vessels. Indeed, *sema3a1/*
sema3a2 and *plxnd1* morphants, as well as the genetic

plxnd1 mutant *out-of-bounds (obd)* display inter-seg- 155
 mental blood vessel patterning defects characterized by
 angiogenic sprouts invading the central region of
 somites. In addition, *Sema3A*/PlexinD1 signaling in qui-
 escent aortic ECs adjacent to somites was found to pro-
 mote the autocrine secretion of a soluble VEGFR1 splice 160
 variant capable of sequestering VEGF and restricting
 blood vessel sprouting to somite boundaries.⁴⁰

Immunohistochemical analysis of the spatial distribu-
 tion of *Sema3A* protein in the developing quail embryo
 was consistent with a negative regulation of vascular pat- 165
 terning.⁴² Fittingly, implantation of *Sema3A* antibody-
 soaked beads in the developing forelimb of chick
 embryos caused substantial alterations in the developing
 vascular pattern; capillaries surrounding the *Sema3A*
 antibody-soaked bead were dilated, disorganized, and 170
 converged toward the bead.⁴² Similarly, retrovirus-medi-
 ated delivery of dominant negative constructs of *Sema3A*
 holoreceptor components in vascular ECs of the develop-
 ing chick embryo impaired blood vessel remodeling.⁴³

The very few *Sema3a* null mice that survive and go 175
 beyond weaning, live longer, and display an altered
 sympathetic cardiac innervation pattern that results in
 sinus bradycardia.⁴⁴ Cardiac-specific overexpression of
Sema3a induces a reduction of sympathetic innervation
 and transgenic animals display susceptibility to ventricu- 180
 lar tachycardia.⁴⁴ Accordingly, it has been reported
 that myocardial overexpression of *Sema3a*⁴⁵ or intrave-
 nous administration of recombinant *Sema3A* protein⁴⁶
 after infarction in rats can reduce the probability of
 ventricular tachycardia that frequently is an associated 185
 response to injury, as a result of attenuated sympathetic
 reinnervation. Moreover, a nonsynonymous polymor-
 phism (I334V, rs138694505A>G) in exon 10 of the
 human *SEMA3A* gene was associated with unexplained
 cardiac arrest and ventricular fibrillation; the axon 190
 repelling activity *SEMA3A*^{I334V} appears significantly
 weaker of that of its wild type counterpart and in the
 hearts of patients sympathetic nerves invade the suben-
 docardial layer.⁴⁷

The angiogenic remodeling of both cephalic plexus 195
 and dorsal longitudinal anatomical vessel into mature
 hierarchically organized vascular trees is severely defec-
 tive in *Sema3a* knockout embryos.⁴³ In addition, *Sem-*
a3a^{-/-} pups that survive until the adulthood present an
 excessive number of glomerular ECs associated with 200
 renal vascular defects.⁴⁸ The reported lack of vascular
 abnormalities in one study on *Sema3a* null mice⁴⁹ could
 be due to the use of an age-and-stage matching strategy
 to compare wild type and *Sema3a* null embryos; indeed,
 age-and-stage matching inherently overlooks the growth 205
 retardation phenotype that, as previously described,⁵⁰
 usually characterize knockout embryos that display

Table 2. *Sema3* and *Sema3* receptor mutants with cardiovascular phenotype.

| Protein | Animal model | Cardiovascular phenotype | References |
|---|--------------|--|--|
| Sema3A | Mouse | General ko | Atrial defects, sinus bradycardia, angiogenic remodelling defect of cephalic and dorsal longitudinal vessels, excessive number of glomerular ECs. 43,44,48 |
| | | EC specific ko | No obvious cardiovascular phenotype 49 Increased number and length of filopodia in retinal tip endothelial cells 52 |
| | Zebrafish | Morphants | Inter-segmental blood vessel patterning defects 39,40 |
| | Chicken | Blocking antibodies, dominant-negative receptor constructs | Vascular patterning alterations, vascular remodelling impairment. 42,43 |
| Sema3B | Mouse | General ko | Cardiovascular phenotype not analyzed 79 |
| Sema3C | Mouse | General ko | Improper septation of the cardiac outflow tract, ventricular septal defects, aortic arch defects 82 |
| Sema3D | Mouse | General ko | Anomalous pulmonary venous connection, atrial septal defects, improper patterning of the coronary veins 88,89 |
| Sema3E | Mouse | General ko | Initially severe vascular defects (e.g., in dorsal aortae patterning) that normalize during development 64,65,68 |
| Sema3F | Mouse | General ko | Cardiovascular phenotype not analyzed 105 |
| Sema3G | Mouse | General ko | No obvious cardiovascular phenotype 91 |
| Nrp1 | Mouse | General ko | Angiogenic remodelling defects of major head and trunk blood vessels, improper septation of the cardiac outflow tract 56 |
| | | <i>Nrp1^{Sema-}</i> EC specific ko | Cardiac defects, lung vascular abnormalities 53-55 Brain vasculature abnormalities, reduced branching and vessels interconnections 106 |
| Nrp2 | Mouse | General ko | No obvious cardiovascular phenotype 107,108 |
| | | Nrp1 and Nrp2 placenta. ¹⁰⁹ | Vascular anomalies in embryos and ⁵³ |
| Nrp1 ^{Sema-;} Nrp2 ^{-/-} | Mouse | General ko | Bilateral atrial enlargement, anomalous origin of the coronary arteries, ventricular septal defect, improper septation of the cardiac outflow tract, no obvious vascular defects 110,111 |
| | | General ko | |
| Plexin A1 | Mouse | General ko | No obvious cardiovascular phenotype |
| Plexin A2 channel-septation with incomplete penetration. ^{112,113} | Mouse | General ko | Persistent truncus arteriosus and lack of aortic and pulmonary ^{112,113} |
| | | General ko | |
| Plexin A2 and Plexin A4 high penetration. ¹¹³ | Mouse | General ko | Cardiovascular defects with ¹¹³ |
| Plexin D1 | Zebrafish | Morphants and <i>obd</i> genetic mutant | Inter-segmental blood vessel patterning defects 39 |
| | Mouse | General ko EC specific ko | Cyanotic after birth, vascular invasion in somite 63 Myocardial defects, reduction of bone microvasculature 62 |

vascular remodeling defects, such as *Sema3a* null mice.⁴³

Of note, endothelial tip cells of murine retinal vascular
210 spouts were found to express much more *Sema3a*
mRNA than stalk ECs,⁵¹ and EC-specific *Sema3a* knock-
out mice were recently described to exhibit a significantly
increased number and length of endothelial tip cell filo-
podia in retinal vascular sprouts.⁵² The latter finding
215 emphasize how paracrine *Sema3A* secreted by non-
vascular cells of adjacent tissues does not rescue the spe-
cific function(s) that autocrine EC-derived *Sema3A* exerts
during sprouting angiogenesis.

The role of Nrp1 in *Sema3A* signaling in ECs appears to
220 be controversial. A *Nrp1^{Sema-}* mouse strain harboring
mutations in a1 domain of Nrp1 that finally impair *Sema3*
protein signaling, at least in neurons, was previously gener-
ated.⁵³ Differently from *Nrp1* null mice, which die by E12.5,
60% of *Nrp1^{Sema-}* mouse was originally reported to survive
225 until P7 and to exhibit cardiac, but not vascular abnormali-
ties.⁵³ However, more recently 2 independent studies^{54,55}

reported how only 18% of *Nrp1^{Sema-}* mouse survive until P4
and present lung vascular abnormalities phenocopying the
so-called alveolar capillary dysplasia, *i.e.* severely reduced
230 capillary density, centrally located and dilated alveolar
capillaries, hypertensive changes in arteriolar walls, anoma-
lous and misaligned pulmonary veins. However, the lack
angiogenic remodeling defects of major head and trunk
blood vessels in *Nrp1^{Sema-}* mice⁵³ and the fact that the vas-
cular phenotype in both *Sema3A*⁴³ and *Nrp1*⁵⁶ knockout
235 mice is, on the contrary, highly severe raises the possibility
that in mutant *Nrp1^{Sema-}* the responsivity of ECs to
Sema3A, albeit reduced, could be, at least in part, main-
tained due to the existence of additional *Sema3A* co-recep-
tors other than Nrp1, such as proteoglycans.^{21,22} Along this
240 line, it is remarkable that some misprojected axon bundles
are present in *Plxna4* null, but neither in *Nrp1*⁵⁷ or in
Nrp1^{Sema-53} mutant mice, implying that Plexin A4 may
deliver Nrp1-independent *Sema3A* signals in some neuro-
nal populations.⁵⁸ Such a scenario would also be compatible
245

with the hypothesis that, similarly to membrane associated Semas, *Sema3A* would directly bind, albeit at very low affinity, and signal *via* plexins.¹⁷ *Sema3A* has been reported to signal through Plexin A1,⁵⁹ Plexin A2,^{18,60} Plexin A4,^{58,61} and Plexin D1⁶² (Table 1). In turn, Plexin D1 was shown to be significantly more efficient than type A plexins in forming high affinity Nrp-dependent holoreceptor complexes for *Sema3A* and *Sema3C*.⁶³ Both Plexin A1 and Plexin A4 were found to be required for *Sema3A*-elicited collapse of cultured ECs.⁶¹ In addition, aortic ring sprouting assays and Boyden chamber assays revealed how *Sema3A* inhibits less efficiently the sprouting of aortic blood vessels or the migration of primary ECs isolated from *Plxnd1*^{-/-} than from wild type animals.⁶² Therefore, *Sema3A* may control *in vivo* vascular morphogenesis by binding with high affinity to co-receptors, such as Nrp1 or proteoglycans, and signal through manifold low-affinity receptors, *e.g.* Plexin A1, Plexin A2, Plexin A4 and Plexin D1 (Table 1).

Sema3E

Sema3E binds to high affinity Plexin D1 in a Nrp1-independent manner⁶⁴ (Table 1). Both in *Sema3e* and *Plxnd1* knockout embryos blood vessels expand ectopically throughout somites causing the loss of the typical stereotyped intersomitic vascular pattern.⁶⁴ However, while *Plxnd1* knockout pups become cyanotic sudden after birth and succumb within 24 hours,⁶³ *Sema3e*^{-/-} mice are viable, fertile and survive throughout adulthood although displaying initially severe vascular defects,^{64,65} thus implying that in the developing embryo Plexin D1 transduces not only the signals of *Sema3E*, but also those elicited by other *Sema3* proteins, such as *Sema3A*⁶² and *Sema3C*.⁶³ Interestingly, both *Sema3A*⁶⁶ and Plexin-D1⁶⁷ null mice share common axial skeletal defects, such as rib fusion and vertebral split. Moreover, selective endothelial *Tie2-cre*-mediated gene inactivation of *Plxnd1* gene in mice induced myocardial defects and skeletal malformations, associated to a strong reduction of the bone microvasculature.⁶² Since Plexin D1 is required for proper blood vessel invasion into the bone, the skeletal defects of *Plxnd1* null mice are most likely secondary to vascular abnormalities.

Sema3E protein produced by the lateral plate mesoderm is required for dorsal aortae patterning and for generating the avascular zones that are located laterally to the dorsal aortae and along the midline.^{65,68} During the vasculogenic phase, instead of smooth paired dorsal aortae, *Sema3e*^{-/-} embryos develop highly branched plexiform vessels that, due to unidentified repulsive signal(s) originating from the lateral plate mesoderm convert into single, unbranched dorsal aortae between E8.25 and E8.75.⁶⁸ It is anticipated that intersegmental blood

vessel patterning defects originally characterized in *Sema3e*^{-/-} embryos⁶⁴ are similarly rescued over time by other repulsive guidance cues. Furthermore, differently from zebrafish *sema3a1/sema3a2* and *plexind1* morphants as well as *obd* mutants,³⁹ the intersomitic blood vessels of *sema3e* zebrafish morphants do not display any angiogenic sprout overshooting phenotype.⁶⁹

Recent studies contributed to shed light on the main pathways that characterize *Sema* signaling through plexins. The intracellular region of plexins is highly conserved and contains 2 large portions that are highly homologous to Ras GAP domains.^{70,71} It has been reported that the Ras GAP-like domain of plexin exert its enzymatic activity on 2 Ras-related small GTPase proteins: R-Ras⁷² and M-Ras.⁷³ However, 2 subsequent studies, albeit reporting a binding between Plexin-D1 or Plexin-B1 and R-Ras, failed to detect any GAP activity toward this small GTPase.^{74,75} More recently, Wang and colleagues further confirmed that the purified cytodomains different plexins do not display any GAP activity on R-Ras or M-Ras.¹² Similarly, a recent study on knock-in mice carrying inactivating mutations in the GAP domains of genes encoding for Plexin D1 and Plexin B2 unveiled a crucial R-Ras and M-Ras independent function for the GAP domain of these 2 plexins in the control of the development of nervous, vascular, and skeletal systems.¹⁰ Wang and colleagues provided instead evidence that purified cytoplasmic regions of different plexins exert their GAP activity on the small GTPase Rap1 and that this function was required for plexin-mediated neuronal growth cone collapse¹² (Fig. 1). Subsequently, Wang and colleagues described the crystal structures of zebrafish Plexin C1 cytoplasmic region in complex with Rap1, thus unveiling the conformational changes and molecular details that allow Rap1-binding by plexins.¹³ It is well known that Rap1-GTP effectively controls vascular morphogenesis⁷⁶ and promotes, *via* talin, the conformational activation of integrins and the ensuing adhesion of different cell types to the extracellular matrix^{76,77} (Fig. 1). It is conceivable that both *Sema3A* and *Sema3E* inhibit integrin mediated adhesion and promote vascular remodeling⁴³ by inhibiting Rap1 GTP loading and integrin activation through the GAP activity of plexins.^{12,13}

Other Sema3 proteins

Sema3B is as an angiogenesis inhibitor and exerts its effect through the binding to Nrp1⁷⁸ (Table 1). *Sema3B* knockout mice are viable and fertile.⁷⁹ An unbiased transcriptomic analysis revealed that in severe forms of human preeclampsia *SEMA3B* is upregulated in and inhibits the differentiation of placental cytotrophoblasts;

furthermore, cytotrophoblasts-derived SEMA3B may act in a paracrine way to impair uterine microvascular ECs functions.⁸⁰

Sema3C protein binds with high affinity to Nrp1-Plexin D1 and, albeit with lower affinity, to Nrp2-PlexinD1 complexes⁶³ (Table 1). Accordingly, Sema3C was recently reported to inhibit angiogenesis by signaling *via* Nrp1 and Plexin D1.⁸¹ Deletion of either *Sema3c*⁸² or *Nrp1*⁵⁶ or *Plxnd1*⁶³ gene causes postnatal lethality due to cardiovascular defects among which the improper septation of the cardiac outflow tract (OFT), resembling the persistent truncus arteriosus observed in humans.⁸³ OFT septation depends on the formation, expansion, and fusion of endocardial cushions, finally resulting into a septal bridge; subsequently second heart field-derived smooth muscle cells invade to myocardialize the septum.⁸⁴ A recent study proposed that neural crest cell-derived Sema3C elicits the Nrp1-dependent endothelial-to-mesenchymal transition that is needed to give rise to the cell population that form the endocardial cushions; in addition, Sema3C-Nrp1 signaling would also drive septum myocardialization.⁸⁵

Sema3D inhibits EC spreading and migration through a Nrp1 and phosphatidylinositol 3 kinase/Akt dependent pathway⁸⁶ (Table 1). Fate mapping studies both in mouse and chick established that Sema3D is expressed in a subpopulation of proepicardial cells that give rise to sinus venosus, a tissue that, at later stages, contributes to the development of the coronary endothelium.⁸⁷ Moreover, Sema3D is expressed in the mesocardial reflections that are located between the splanchnic mesoderm and the venous pole of the heart.⁸⁸ In the developing embryo, Sema3D would exert a repulsive guidance effect to constrain and to direct pulmonary venous ECs toward the left atrium.⁸⁸ Consistently, *Sema3d* null mice exhibit anomalous pulmonary venous connection (APVC) and a c.1806T>A missense mutation that results in the F602L substitution was present in a partial APVC patient.⁸⁸ SEMA3D F602L binding to Nrp1 and ability to repel the migration of cultured ECs is significantly reduced.⁸⁸ Sema3D was recently reported to be expressed in the left anterior atrioventricular groove to repel venous ECs from aberrantly connecting with the left atrium.⁸⁹ It appears that in venous ECs the inhibitory Sema3D signals are conveyed through a Nrp1-ErbB2 holoreceptor complex.⁸⁹

Sema3F binds with high affinity to Nrp2 and, with lower affinity, to Nrp1⁹⁰ (Table 1). Although it is well known that Sema3F is an effective inhibitor of cancer angiogenesis (for review see ref. 5), so far no defects in cardiovascular development were reported in *Sema3f* null mice.

Sema3G binds with high affinity to Nrp2 and, with lower affinity, to Nrp1⁹¹ (Table 1). *Sema3g*^{-/-} mice were

reported to be viable and to do not display any obvious vascular phenotype.⁹¹ Sema3G displayed preferential arterial expression in all organs during embryonic development (from E9.5) and postnatally throughout adolescence, while it was downregulated in the adult. Sema3G is produced by ECs and acts as a positive regulator of angiogenic functions both in an autocrine and paracrine way, by promoting smooth muscle cell migration.⁹¹

Disclosure of potential conflicts of interest

No potential conflicts of interest were disclosed. 410

Funding

This work was supported by grants from: Italian Association for Cancer Research (AIRC-IG grant # 15645 to E.G.; #13016 and # 16702 to G.S.); FPRC-ONLUS Grant “MIUR 2010 Vaschetto - 5 per mille 2010 MIUR” (to E.G. and G.S.); Swiss National Science Foundation (SNSF), Sinergia Grant (# CRSII3 160742/1), (to E.G.); Telethon Italy (GGP09175) (to G.S.); Associazione ‘Augusto per la Vita’ (to G.S.). D.R. was supported by FPRC-ONLUS Grant “MIUR 2010 Vaschetto-Chiodo Fellowship.” 420

References

- [1] Walls JR, Coultas L, Rossant J, Henkelman RM. Three-dimensional analysis of vascular development in the mouse embryo. *PLoS One* 2008; 3:e2853; PMID:18682734; <http://dx.doi.org/10.1371/journal.pone.0002853> 425
- [2] Herbert SP, Stainier DY. Molecular control of endothelial cell behaviour during blood vessel morphogenesis. *Nat Rev Mol Cell Biol* 2011; 12:551-64; PMID:21860391; <http://dx.doi.org/10.1038/nrm3176>
- [3] Epstein JA, Aghajanian H, Singh MK. Semaphorin signaling in cardiovascular development. *Cell Metab* 2015; 21:163-73; PMID:25651171; <http://dx.doi.org/10.1016/j.cmet.2014.12.015> 430
- [4] Luo Y, Raible D, Raper JA. Collapsin: a protein in brain that induces the collapse and paralysis of neuronal growth cones. *Cell* 1993; 75:217-27; PMID:8402908; [http://dx.doi.org/10.1016/0092-8674\(93\)80064-L](http://dx.doi.org/10.1016/0092-8674(93)80064-L)
- [5] Kolodkin AL, Matthes DJ, Goodman CS. The semaphorin genes encode a family of transmembrane and secreted growth cone guidance molecules. *Cell* 1993; 75:1389-99; PMID:8269517; [http://dx.doi.org/10.1016/0092-8674\(93\)90625-Z](http://dx.doi.org/10.1016/0092-8674(93)90625-Z) 440
- [6] Kruger RP, Auerand J, Guan KL. Semaphorins command cells to move. *Nat Rev Mol Cell Biol* 2005; 6:789-800; PMID:16314868; <http://dx.doi.org/10.1038/nrm1740> 445
- [7] Neufeld G, Sabag AD, Rabinovicz N, Kessler O. Semaphorins in angiogenesis and tumor progression. *Cold Spring Harb Perspect Med* 2012; 2:a006718; PMID:22315716; <http://dx.doi.org/10.1101/cshperspect.a006718> 450
- [8] Serini G, Bussolino F, Maione F, Giraudo E. Class 3 semaphorins: physiological vascular normalizing agents

- for anti-cancer therapy. *J Intern Med* 2013; 273:138-55; PMID:23198760; <http://dx.doi.org/10.1111/joim.12017>
- 455 [9] Siebold C, Jones EY. Structural insights into semaphorins and their receptors. *Semin Cell Dev Biol* 2013; 24:139-45; PMID:23253452; <http://dx.doi.org/10.1016/j.semcdb.2012.11.003>
- [10] Worzfeld T, Swiercz JM, Sentürk A, Genz B, Korostylev A, Deng S, Xia J, Hoshino M, Epstein JA, Chan AM, et al. Genetic dissection of plexin signaling in vivo. *Proc Natl Acad Sci U S A* 2014; 111:2194-9; PMID:24469813; <http://dx.doi.org/10.1073/pnas.1308418111>
- 460 [11] Worzfeld T, Offermanns S. Semaphorins and plexins as therapeutic targets. *Nat Rev Drug Discov* 2014; 13:603-21; PMID:25082288; <http://dx.doi.org/10.1038/nrd4337>
- 465 [12] Wang Y, He H, Srivastava N, Vikarunnessa S, Chen YB, Jiang J, Cowan CW, Zhang X. Plexins are GTPase-activating proteins for Rap and are activated by induced dimerization. *Sci Signal* 2012; 5:ra6; PMID:22253263
- [13] Wang Y, Pascoe HG, Brautigam CA, He H, Zhang X. Structural basis for activation and non-canonical catalysis of the Rap GTPase activating protein domain of plexin. *Elife* 2013; 2:e01279; PMID:24137545
- 475 [14] Antipenko A, Himanen JP, van Leyen K, Nardi-Dei V, Lesniak J, Barton WA, Rajashankar KR, Lu M, Hoemme C, Puschel AW, et al. Structure of the semaphorin-3A receptor binding module. *Neuron* 2003; 39:589-98; PMID:12925274; [http://dx.doi.org/10.1016/S0896-6273\(03\)00502-6](http://dx.doi.org/10.1016/S0896-6273(03)00502-6)
- 480 [15] Liu H, Juo ZS, Shim AH, Focia PJ, Chen X, Garcia KC, He X. Structural basis of semaphorin-plexin recognition and viral mimicry from Sema7A and A39R complexes with PlexinC1. *Cell* 2010; 142:749-61; PMID:20727575; <http://dx.doi.org/10.1016/j.cell.2010.07.040>
- 485 [16] Janssen BJ, Robinson RA, Pérez-Brangulí F, Bell CH, Mitchell KJ, Siebold C, Jones EY. Structural basis of semaphorin-plexin signalling. *Nature* 2010; 467:1118-22; PMID:20877282; <http://dx.doi.org/10.1038/nature09468>
- 490 [17] Nogi T, Yasui N, Mihara E, Matsunaga Y, Noda M, Yamashita N, Toyofuku T, Uchiyama S, Goshima Y, Kumanogoh A, et al. Structural basis for semaphorin signalling through the plexin receptor. *Nature* 2010; 467:1123-7; PMID:20881961; <http://dx.doi.org/10.1038/nature09473>
- 495 [18] Janssen BJ, Malinauskas T, Weir GA, Cader MZ, Siebold C, Jones EY. Neuropilins lock secreted semaphorins onto plexins in a ternary signaling complex. *Nat Struct Mol Biol* 2012; 19:1293-9; PMID:23104057; <http://dx.doi.org/10.1038/nsmb.2416>
- 500 [19] Adams RH, Lohrum M, Klostermann A, Betz H, Puschel AW. The chemorepulsive activity of secreted semaphorins is regulated by furin-dependent proteolytic processing. *EMBO J* 1997; 16:6077-86; PMID:9321387; <http://dx.doi.org/10.1093/emboj/16.20.6077>
- 505 [20] Koppel AM, Raper JA. Collapsin-1 covalently dimerizes, and dimerization is necessary for collapsing activity. *J Biol Chem* 1998; 273:15708-13; PMID:9624167; <http://dx.doi.org/10.1074/jbc.273.25.15708>
- 510 [21] Casazza A, Laoui D, Wenes M, Rizzolio S, Bassani N, Mambretti M, Deschoemaeker S, Van Ginderachter JA, Tamagnone L, Mazzone M. Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity. *Cancer Cell* 2013; 24:695-709; PMID:24332039; <http://dx.doi.org/10.1016/j.ccr.2013.11.007>
- [22] Pang HB, Braun GB, Ruoslahti E. Neuropilin-1 and heparan sulfate proteoglycans cooperate in cellular uptake of nanoparticles functionalized by cationic cell-penetrating peptides. *Sci Adv* 2015; 1:e1500821; PMID:26601141; <http://dx.doi.org/10.1126/sciadv.1500821>
- [23] Guo HF, Vander Kooi CW. Neuropilin functions as an essential cell surface receptor. *J Biol Chem* 2015; 290:29120-6; PMID:26451046; <http://dx.doi.org/10.1074/jbc.R115.687327>
- 525 [24] Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. *Cell* 1998; 92:735-45; PMID:9529250; [http://dx.doi.org/10.1016/S0092-8674\(00\)81402-6](http://dx.doi.org/10.1016/S0092-8674(00)81402-6)
- [25] Parker Matthew W, Linkugel Andrew D, Goel Hira L, Wu T, Mercurio Arthur M, Vander Kooi Craig W. Structural basis for VEGF-C binding to Neuropilin-2 and sequestration by a soluble splice form. *Structure* 2015; 23:677-87; PMID:25752543; <http://dx.doi.org/10.1016/j.str.2015.01.018>
- 535 [26] Giger RJ, Urquhart ER, Gillespie SK, Levengood DV, Ginty DD, Kolodkin AL. Neuropilin-2 is a receptor for semaphorin IV: insight into the structural basis of receptor function and specificity. *Neuron* 1998; 21:1079-92; PMID:9856463; [http://dx.doi.org/10.1016/S0896-6273\(00\)80625-X](http://dx.doi.org/10.1016/S0896-6273(00)80625-X)
- [27] Nakamura F, Tanaka M, Takahashi T, Kalb RG, Strittmatter SM. Neuropilin-1 extracellular domains mediate semaphorin D/III-induced growth cone collapse. *Neuron* 1998; 21:1093-100; PMID:9856464; [http://dx.doi.org/10.1016/S0896-6273\(00\)80626-1](http://dx.doi.org/10.1016/S0896-6273(00)80626-1)
- 545 [28] Renzi MJ, Feiner L, Koppel AM, Raper JA. A dominant negative receptor for specific secreted semaphorins is generated by deleting an extracellular domain from neuropilin-1. *J Neurosci* 1999; 19:7870-80; PMID:10479689
- [29] Chen H, He Z, Bagri A, Tessier-Lavigne M. Semaphorin-neuropilin interactions underlying sympathetic axon responses to class III semaphorins. *Neuron* 1998; 21:1283-90; PMID:9883722; [http://dx.doi.org/10.1016/S0896-6273\(00\)80648-0](http://dx.doi.org/10.1016/S0896-6273(00)80648-0)
- 550 [30] Parker MW, Xu P, Guo HF, Vander Kooi CW. Mechanism of selective VEGF-A binding by neuropilin-1 reveals a basis for specific ligand inhibition. *PLoS One* 2012; 7:e49177; PMID:23145112; <http://dx.doi.org/10.1371/journal.pone.0049177>
- 560 [31] Parker MW, Xu P, Li X, Vander Kooi CW. Structural basis for the selective vascular endothelial growth factor-A (VEGF-A) binding to neuropilin-1. *J Biol Chem* 2012; 287(14):11082-9; PMID:22318724; <http://dx.doi.org/10.1074/jbc.M111.331140>
- 565 [32] Parker MW, Hellman LM, Xu P, Fried MG, Vander Kooi CW. Furin processing of semaphorin 3F determines its anti-angiogenic activity by regulating direct binding and competition for neuropilin. *Biochemistry* 2010; 49:4068-75; PMID:20387901; <http://dx.doi.org/10.1021/bi100327r>
- 570 [33] Guo HF, Li X, Parker MW, Waltenberger J, Becker PM, Vander Kooi CW. Mechanistic basis for the potent anti-

Q4

Q5

- angiogenic activity of semaphorin 3F. *Biochemistry* 2013; 52:7551-8; PMID:24079887; <http://dx.doi.org/10.1021/bi401034q>
- 580 [34] Miao HQ, Soker S, Feiner L, Alonso JL, Raper JA, Klagsbrun M. Neuropilin-1 mediates collapsin-1/semaphorin III inhibition of endothelial cell motility: functional competition of collapsin-1 and vascular endothelial growth factor-165. *J Cell Biol* 1999; 146:233-42; PMID:10402473
- 585 [35] Gu C, Limberg BJ, Whitaker GB, Perman B, Leahy DJ, Rosenbaum JS, Ginty DD, Kolodkin AL. Characterization of neuropilin-1 structural features that confer binding to semaphorin 3A and vascular endothelial growth factor 165. *J Biol Chem* 2002; 277:18069-76; PMID:11886873; <http://dx.doi.org/10.1074/jbc.M201681200>
- 590 [36] Narazaki M, Tosato G. Ligand-induced internalization selects use of common receptor neuropilin-1 by VEGF165 and semaphorin3A. *Blood* 2006; 107:3892-901; PMID:16424390; <http://dx.doi.org/10.1182/blood-2005-10-4113>
- 595 [37] Appleton BA, Wu P, Maloney J, Yin J, Liang WC, Stawicki S, Mortara K, Bowman KK, Elliott JM, Desmarais W, et al. Structural studies of neuropilin/antibody complexes provide insights into semaphorin and VEGF binding. *EMBO J* 2007; 26:4902-12; PMID:17989695; <http://dx.doi.org/10.1038/sj.emboj.7601906>
- 600 [38] Parker MW, Guo HF, Li X, Linkugel AD, Vander Kooi CW. Function of members of the neuropilin family as essential pleiotropic cell surface receptors. *Biochemistry* 2012; 51:9437-46; PMID:23116416; <http://dx.doi.org/10.1021/bi3012143>
- 605 [39] Torres-Vázquez J, Gitler AD, Fraser SD, Berk JD, Van N Pham, Fishman MC, Childs S, Epstein JA, Weinstein BM. Semaphorin-plexin signaling guides patterning of the developing vasculature. *Dev Cell* 2004; 7:117-23; ; <http://dx.doi.org/10.1016/j.devcel.2004.06.008>
- 610 [40] Zygmunt T, Gay CM, Blondelle J, Singh MK, Flaherty KM, Means PC, Herwig L, Krudewig A, Belting HG, Affolter M, et al. Semaphorin-PlexinD1 signaling limits angiogenic potential via the VEGF decoy receptor sFlt1. *Dev Cell* 2011; 21:301-14; PMID:21802375; <http://dx.doi.org/10.1016/j.devcel.2011.06.033>
- 615 [41] Meyer A, Scharl M. Gene and genome duplications in vertebrates: the one-to-four (-to-eight in fish) rule and the evolution of novel gene functions. *Curr Opin Cell Biol* 1999; 11:699-704; PMID:10600714; [http://dx.doi.org/10.1016/S0955-0674\(99\)00039-3](http://dx.doi.org/10.1016/S0955-0674(99)00039-3)
- 620 [42] Bates D, Taylor GI, Minichiello J, Farlie P, Cichowitz A, Watson N, Klagsbrun M, Mamluk R, Newgreen DF. Neurovascular congruence results from a shared patterning mechanism that utilizes Semaphorin3A and Neuropilin-1. *Dev Biol* 2003; 255:77-98; PMID:12618135; [http://dx.doi.org/10.1016/S0012-1606\(02\)00045-3](http://dx.doi.org/10.1016/S0012-1606(02)00045-3)
- 625 [43] Serini G, Valdembri D, Zanivan S, Morterra G, Burkhardt C, Caccavari F, Zammataro L, Primo L, Tamagnone L, Logan M, et al. Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. *Nature* 2003; 424:391-7; PMID:12879061; <http://dx.doi.org/10.1038/nature01784>
- 635 [44] Ieda M, Kanazawa H, Kimura K, Hattori F, Ieda Y, Taniguchi M, Lee JK, Matsumura K, Tomita Y, Miyoshi S, et al. Sema3a maintains normal heart rhythm through sympathetic innervation patterning. *Nat Med* 2007; 13:604-12; PMID:17417650; <http://dx.doi.org/10.1038/nm1570>
- [45] Chen RH, Li YG, Jiao KL, Zhang PP, Sun Y, Zhang LP, Fong XF, Li W, Yu Y. Overexpression of Sema3a in myocardial infarction border zone decreases vulnerability of ventricular tachycardia post-myocardial infarction in rats. *J Cell Mol Med* 2013; 17:608-16; PMID:23711091; <http://dx.doi.org/10.1111/jcmm.12035>
- [46] Hu H, Xuan Y, Xue M, Cheng W, Wang Y, Li X, Yin J, Yang N, Shi Y, Yan S. Semaphorin 3A attenuates cardiac autonomic disorders and reduces inducible ventricular arrhythmias in rats with experimental myocardial infarction. *BMC Cardiovasc Disord* 2016; 16:16; PMID:26787044; <http://dx.doi.org/10.1186/s12872-016-0192-8>
- [47] Nakano Y, Chayama K, Ochi H, Toshishige M, Hayashida Y, Miki D, Hayes CN, Suzuki H, Tokuyama T, Oda N, et al. A nonsynonymous polymorphism in semaphorin 3A as a risk factor for human unexplained cardiac arrest with documented ventricular fibrillation. *PLoS Genet* 2013; 9:e1003364; PMID:23593010; <http://dx.doi.org/10.1371/journal.pgen.1003364>
- [48] Reidy KJ, Villegas G, Teichman J, Veron D, Shen W, Jimenez J, Thomas D, Tufro A. Semaphorin3a regulates endothelial cell number and podocyte differentiation during glomerular development. *Development* 2009; 136:3979-89; PMID:19906865; <http://dx.doi.org/10.1242/dev.037267>
- [49] Vieira JM, Schwarz Q, Ruhrberg C. Selective requirements for NRP1 ligands during neurovascular patterning. *Development* 2007; 134:1833-43; PMID:17428830; <http://dx.doi.org/10.1242/dev.002402>
- [50] Hamada K, Sasaki T, Koni PA, Natsui M, Kishimoto H, Sasaki J, Yajima N, Horie Y, Hasegawa G, Naito M, et al. The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis. *Genes Dev* 2005; 19:2054-65; PMID:16107612; <http://dx.doi.org/10.1101/gad.1308805>
- [51] Strasser GA, Kaminker JS, Tessier-Lavigne M. Microarray analysis of retinal endothelial tip cells identifies CXCR4 as a mediator of tip cell morphology and branching. *Blood* 2010; 115:5102-10; PMID:20154215; <http://dx.doi.org/10.1182/blood-2009-07-230284>
- [52] Ochsenbein AM, Karaman S, Proulx ST, Berchtold M, Jurisic G, Stoeckli ET, Detmar M. Endothelial cell-derived semaphorin 3A inhibits filopodia formation by blood vascular tip cells. *Development* 2016; 143:589-94; PMID:26884395; <http://dx.doi.org/10.1242/dev.127670>
- [53] Gu C, Rodriguez ER, Reimert DV, Shu T, Fritzsche B, Richards LJ, Kolodkin AL, Ginty DD. Neuropilin-1 conveys semaphorin and VEGF signaling during neural and cardiovascular development. *Dev Cell* 2003; 5:45-57; PMID:12852851; [http://dx.doi.org/10.1016/S1534-5807\(03\)00169-2](http://dx.doi.org/10.1016/S1534-5807(03)00169-2)
- [54] Joza S, Wang J, Tseu I, Ackerley C, Post M. Fetal, but not postnatal, deletion of semaphorin-neuropilin-1 signaling affects murine alveolar development. *Am J Respir Cell Mol Biol* 2013; 49:627-36; PMID:23713442; <http://dx.doi.org/10.1165/rcmb.2012-0407OC>
- [55] Joza S, Wang J, Fox E, Hillman V, Ackerley C, Post M. Loss of semaphorin-neuropilin-1 signaling causes

- dysmorphic vascularization reminiscent of alveolar capillary dysplasia. *Am J Pathol* 2012; 181:2003-17; PMID:23063659; <http://dx.doi.org/10.1016/j.ajpath.2012.08.037>
- 705 [56] Kawasaki T, Kitsukawa T, Bekku Y, Matsuda Y, Sanbo M, Yagi T, Fujisawa H. A requirement for neuropilin-1 in embryonic vessel formation. *Development* 1999; 126:4895-902; PMID:10518505
- 710 [57] Kitsukawa T, Shimizu M, Sanbo M, Hirata T, Taniguchi M, Bekku Y, Yagi T, Fujisawa H. Neuropilin-semaphorin III/D-mediated chemorepulsive signals play a crucial role in peripheral nerve projection in mice. *Neuron* 1997; 19:995-1005; PMID:9390514; [http://dx.doi.org/10.1016/S0896-6273\(00\)80392-X](http://dx.doi.org/10.1016/S0896-6273(00)80392-X)
- 715 [58] Yaron A, Huang PH, Cheng HJ, Tessier-Lavigne M. Differential requirement for Plexin-A3 and -A4 in mediating responses of sensory and sympathetic neurons to distinct class 3 Semaphorins. *Neuron* 2005; 45:513-23; PMID:15721238; <http://dx.doi.org/10.1016/j.neuron.2005.01.013>
- 720 [59] Takahashi T, Fournier A, Nakamura F, Wang LH, Murakami Y, Kalb RG, Fujisawa H, Strittmatter SM. Plexin-neuropilin-1 complexes form functional semaphorin-3A receptors. *Cell* 1999; 99:59-69; PMID:10520994; [http://dx.doi.org/10.1016/S0092-8674\(00\)80062-8](http://dx.doi.org/10.1016/S0092-8674(00)80062-8)
- 725 [60] Takahashi T, Strittmatter SM. PlexinA1 autoinhibition by the plexin sema domain. *Neuron* 2001; 29:429-39; PMID:11239433; [http://dx.doi.org/10.1016/S0896-6273\(01\)00216-1](http://dx.doi.org/10.1016/S0896-6273(01)00216-1)
- 730 [61] Kigel B, Rabinowicz N, Varshavsky A, Kessler O, Neufeld G. Plexin-A4 promotes tumor progression and tumor angiogenesis by enhancement of VEGF and bFGF signaling. *Blood* 2011; 118:4285-96; PMID:21832283; <http://dx.doi.org/10.1182/blood-2011-03-341388>
- 735 [62] Zhang Y, Singh MK, Degenhardt KR, Lu MM, Bennett J, Yoshida Y, Epstein JA. Tie2Cre-mediated inactivation of plexinD1 results in congenital heart, vascular and skeletal defects. *Dev Biol* 2009; 325:82-93; PMID:18992737; <http://dx.doi.org/10.1016/j.ydbio.2008.09.031>
- 740 [63] Gitler AD, Lu MM, Epstein JA. PlexinD1 and semaphorin signaling are required in endothelial cells for cardiovascular development. *Dev Cell* 2004; 7:107-16; PMID:15239958; <http://dx.doi.org/10.1016/j.devcel.2004.06.002>
- 745 [64] Gu C, Yoshida Y, Livet J, Reimert DV, Mann F, Merte J, Henderson CE, Jessell TM, Kolodkin AL, Ginty DD. Semaphorin 3E and plexin-D1 control vascular pattern independently of neuropilins. *Science* 2005; 307:265-8; PMID:15550623; <http://dx.doi.org/10.1126/science.1105416>
- 750 [65] Meadows SM, Fletcher PJ, Moran C, Xu K, Neufeld G, Chauvet S, Mann F, Krieg PA, Cleaver O. Integration of repulsive guidance cues generates avascular zones that shape mammalian blood vessels. *Circ Res* 2012; 110:34-46; PMID:22076636; <http://dx.doi.org/10.1161/CIRCRESAHA.111.249847>
- 755 [66] Behar O, Golden JA, Mashimo H, Schoen FJ, Fishman MC. Semaphorin III is needed for normal patterning and growth of nerves, bones and heart. *Nature* 1996; 383:525-8; PMID:8849723; <http://dx.doi.org/10.1038/383525a0>
- 760 [67] Kanda T, Yoshida Y, Izu Y, Nifuji A, Ezura Y, Nakashima K, Noda M. PlexinD1 deficiency induces defects in axial skeletal morphogenesis. *J Cell Biochem* 2007; 101:1329-37; PMID:17477353; <http://dx.doi.org/10.1002/jcb.21306>
- [68] Meadows SM, Ratliff LA, Singh MK, Epstein JA, Cleaver O. Resolution of defective dorsal aortae patterning in *Sema3E*-deficient mice occurs via angiogenic remodeling. *Dev Dyn* 2013; 242:580-90; PMID:23444297; <http://dx.doi.org/10.1002/dvdy.23949>
- [69] Lamont RE, Lamont EJ, Childs SJ. Antagonistic interactions among Plexins regulate the timing of intersegmental vessel formation. *Dev Biol* 2009; 331:199-209; PMID:19422817; <http://dx.doi.org/10.1016/j.ydbio.2009.04.037>
- [70] Rohm B, Rahim B, Kleiber B, Hovatta I, Püschel AW. The semaphorin 3A receptor may directly regulate the activity of small GTPases. *FEBS Lett* 2000; 486:68-72; PMID:11108845; [http://dx.doi.org/10.1016/S0014-5793\(00\)02240-7](http://dx.doi.org/10.1016/S0014-5793(00)02240-7)
- [71] Hu H, Marton TF, Goodman CS. Plexin B mediates axon guidance in *Drosophila* by simultaneously inhibiting active Rac and enhancing RhoA signaling. *Neuron* 2001; 32:39-51; PMID:11604137; [http://dx.doi.org/10.1016/S0896-6273\(01\)00453-6](http://dx.doi.org/10.1016/S0896-6273(01)00453-6)
- [72] Oinuma I, Ishikawa Y, Katoh H, Negishi M. The Semaphorin 4D receptor Plexin-B1 is a GTPase activating protein for R-Ras. *Science* 2004; 305:862-5; PMID:15297673; <http://dx.doi.org/10.1126/science.1097545>
- [73] Saito Y, Oinuma I, Fujimoto S, Negishi M. Plexin-B1 is a GTPase activating protein for M-Ras, remodelling dendrite morphology. *EMBO Rep* 2009; 10:614-21; PMID:19444311; <http://dx.doi.org/10.1038/embor.2009.63>
- [74] Sakurai A, Gavard J, Annas-Linhares Y, Basile JR, Amornphimoltham P, Palmby TR, Yagi H, Zhang F, Randazzo PA, Li X, et al. Semaphorin 3E initiates antiangiogenic signaling through plexin D1 by regulating Arf6 and R-Ras. *Mol Cell Biol* 2010; 30:3086-98; PMID:20385769; <http://dx.doi.org/10.1128/MCB.01652-09>
- [75] Tong Y, Hota PK, Penachioni JY, Hamaneh MB, Kim S, Alviani RS, Shen L, He H, Tempel W, Tamagnone L, et al. Structure and function of the intracellular region of the plexin-b1 transmembrane receptor. *J Biol Chem* 2009; 284:35962-72; PMID:19843518; <http://dx.doi.org/10.1074/jbc.M109.056275>
- [76] Chrzanowska-Wodnicka M. Distinct functions for Rap1 signaling in vascular morphogenesis and dysfunction. *Exp Cell Res* 2013; 319:2350-9; PMID:23911990; <http://dx.doi.org/10.1016/j.yexcr.2013.07.022>
- [77] Calderwood DA, Campbell ID, Critchley DR. Talins and kindlins: partners in integrin-mediated adhesion. *Nat Rev Mol Cell Biol* 2013; 14:503-17; PMID:23860236; <http://dx.doi.org/10.1038/nrm3624>
- [78] Varshavsky A, Kessler O, Abramovitch S, Kigel B, Zaffryar S, Akiri G, Neufeld G. Semaphorin-3B is an angiogenesis inhibitor that is inactivated by furin-like pro-protein convertases. *Cancer Res* 2008; 68:6922-31; PMID:18757406; <http://dx.doi.org/10.1158/0008-5472.CAN-07-5408>
- [79] Falk J, Julien F, Bechara A, Fiore R, Nawabi H, Zhou H, Hoyo-Becerra C, Bozon M, Rougon G, Grumet M, et al. Dual functional activity of semaphorin 3B is required for positioning the anterior commissure. *Neuron* 2005; 48:63-75; PMID:16202709; <http://dx.doi.org/10.1016/j.neuron.2005.10.024>

- 825 [80] Zhou Y, Gormley MJ, Hunkapiller NM, Kapidzic M, Stolyarov Y, Feng V, Nishida M, Drake PM, Bianco K, Wang F, et al. Reversal of gene dysregulation in cultured cytotrophoblasts reveals possible causes of preeclampsia. *J Clin Invest* 2013; 123:2862-72; PMID:23934129; <http://dx.doi.org/10.1172/JCI66966>
- 830 [81] Yang WJ, Hu J, Uemura A, Tetzlaff F, Augustin HG, Fischer A. Semaphorin-3C signals through Neuropilin-1 and PlexinD1 receptors to inhibit pathological angiogenesis. *EMBO Mol Med* 2015; 7:1267-84; PMID:26194913; <http://dx.doi.org/10.15252/emmm.201404922>
- 835 [82] Feiner L, Webber AL, Brown CB, Lu MM, Jia L, Feinstein P, Mombaerts P, Epstein JA, Raper JA. Targeted disruption of semaphorin 3C leads to persistent truncus arteriosus and aortic arch interruption. *Development* 2001; 128:3061-70; PMID:11688556
- 840 [83] Crupi G, Macartney FJ, Anderson RH. Persistent truncus arteriosus. A study of 66 autopsy cases with special reference to definition and morphogenesis. *Am J Cardiol* 1977; 40:569-78; PMID:910720; [http://dx.doi.org/10.1016/0002-9149\(77\)90073-X](http://dx.doi.org/10.1016/0002-9149(77)90073-X)
- 845 [84] Sugishita Y, Watanabe M, Fisher SA. The development of the embryonic outflow tract provides novel insights into cardiac differentiation and remodeling. *Trends Cardiovasc Med* 2004; 14:235-41; PMID:15451515; <http://dx.doi.org/10.1016/j.tcm.2004.06.004>
- 850 [85] Plein A, Calmont A, Fantin A, Denti L, Anderson NA, Scambler PJ, Ruhrberg C. Neural crest-derived SEMA3C activates endothelial NRP1 for cardiac outflow tract septation. *J Clin Invest* 2015; 125:2661-76; PMID:26053665; <http://dx.doi.org/10.1172/JCI79668>
- 855 [86] Aghajanian H, Choi C, Ho VC, Gupta M, Singh MK, Epstein JA. Semaphorin 3d and semaphorin 3e direct endothelial motility through distinct molecular signaling pathways. *J Biol Chem* 2014; 289:17971-9; PMID:24825896; <http://dx.doi.org/10.1074/jbc.M113.544833>
- 860 [87] Katz TC, Singh MK, Degenhardt K, Rivera-Feliciano J, Johnson RL, Epstein JA, Tabin CJ. Distinct compartments of the proepicardial organ give rise to coronary vascular endothelial cells. *Dev Cell* 2012; 22:639-50; PMID:22421048; <http://dx.doi.org/10.1016/j.devcel.2012.01.012>
- [88] Degenhardt K, Singh MK, Aghajanian H, Massera D, Wang Q, Li J, Li L, Choi C, Yzaguirre AD, Francey LJ, et al. Semaphorin 3d signaling defects are associated with anomalous pulmonary venous connections. *Nat Med* 2013; 19:760-5; PMID:23685842; <http://dx.doi.org/10.1038/nm.3185>
- 870 [89] Aghajanian H, Cho YK, Manderfield LJ, Herling MR, Gupta M, Ho VC, Li L, Degenhardt K, Aharonov A, Tzahor E, et al. Coronary vasculature patterning requires a novel endothelial ErbB2 holoreceptor. *Nat Commun* 2016; 7:12038; PMID:27356767; <http://dx.doi.org/10.1038/ncomms12038>
- 875 [90] Chen H, Chedotal A, He Z, Goodman CS, Tessier-Lavigne M. Neuropilin-2, a novel member of the neuropilin family, is a high affinity receptor for the semaphorins Sema E and Sema IV but not Sema III. *Neuron* 1997; 19:547-59; PMID:9331348; [http://dx.doi.org/10.1016/S0896-6273\(00\)80371-2](http://dx.doi.org/10.1016/S0896-6273(00)80371-2)
- 880 [91] Kutschera S, Weber H, Weick A, De Smet F, Genove G, Takemoto M, Prahst C, Riedel M, Mikelis C, Baulande S, et al. Differential endothelial transcriptomics identifies semaphorin 3G as a vascular class 3 semaphorin. *Arterioscler Thromb Vasc Biol* 2011; 31:151-9; PMID:20947821; <http://dx.doi.org/10.1161/ATVBAHA.110.215871> 890
- [92] He Z, Tessier-Lavigne M. Neuropilin is a receptor for the axonal chemorepellent Semaphorin III. *Cell* 1997; 90:739-51; PMID:9288753; [http://dx.doi.org/10.1016/S0092-8674\(00\)80534-6](http://dx.doi.org/10.1016/S0092-8674(00)80534-6)
- [93] Kolodkin AL, Levengood DV, Rowe EG, Tai YT, Giger RJ, Ginty DD. Neuropilin is a semaphorin III receptor. *Cell* 1997; 90:753-62; PMID:9288754; [http://dx.doi.org/10.1016/S0092-8674\(00\)80535-8](http://dx.doi.org/10.1016/S0092-8674(00)80535-8) 895
- [94] Tamagnone L, Artigiani S, Chen H, He Z, Ming GI, Song H, Chedotal A, Winberg ML, Goodman CS, Poo M, et al. Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. *Cell* 1999; 99:71-80; PMID:10520995; [http://dx.doi.org/10.1016/S0092-8674\(00\)80063-X](http://dx.doi.org/10.1016/S0092-8674(00)80063-X)
- [95] Cheng HJ, Bagri A, Yaron A, Stein E, Pleasure SJ, Tessier-Lavigne M. Plexin-A3 mediates semaphorin signaling and regulates the development of hippocampal axonal projections. *Neuron* 2001; 32:249-63; PMID:11683995; [http://dx.doi.org/10.1016/S0896-6273\(01\)00478-0](http://dx.doi.org/10.1016/S0896-6273(01)00478-0)
- [96] Takahashi T, Nakamura F, Jin Z, Kalb RG, Strittmatter SM. Semaphorins A and E act as antagonists of neuropilin-1 and agonists of neuropilin-2 receptors. *Nat Neurosci* 1998; 1:487-93; PMID:10196546; <http://dx.doi.org/10.1038/2203> 910
- [97] Rohm B, Ottemeyer A, Lohrum M, Puschel AW. Plexin/neuropilin complexes mediate repulsion by the axonal guidance signal semaphorin 3A. *Mech Dev* 2000; 93:95-104; PMID:10781943; [http://dx.doi.org/10.1016/S0925-4773\(00\)00269-0](http://dx.doi.org/10.1016/S0925-4773(00)00269-0) 915
- [98] Brown CB, Feiner L, Lu MM, Li J, Ma X, Webber AL, Jia L, Raper JA, Epstein JA. PlexinA2 and semaphorin signaling during cardiac neural crest development. *Development* 2001; 128:3071-80; PMID:11688557
- [99] Chauvet S, Cohen S, Yoshida Y, Fekrane L, Livet J, Gayet O, Segu L, Buhot MC, Jessell TM, Henderson CE, et al. Gating of Sema3E/PlexinD1 signaling by neuropilin-1 switches axonal repulsion to attraction during brain development. *Neuron* 2007; 56:807-22; PMID:18054858; <http://dx.doi.org/10.1016/j.neuron.2007.10.019> 925
- [100] Feiner L, Koppel AM, Kobayashi H, Raper JA. Secreted chick semaphorins bind recombinant neuropilin with similar affinities but bind different subsets of neurons in situ. *Neuron* 1997; 19:539-45; PMID:9331347; [http://dx.doi.org/10.1016/S0896-6273\(00\)80370-0](http://dx.doi.org/10.1016/S0896-6273(00)80370-0) 930
- [101] Wolman MA, Liu Y, Tawarayama H, Shoji W, Halloran MC. Repulsion and attraction of axons by Semaphorin3D are mediated by different neuropilins in vivo. *J Neurosci* 2004; 24:8428-35; PMID:15456815; <http://dx.doi.org/10.1523/JNEUROSCI.2349-04.2004> 935
- [102] Miyazaki N, Furuyama T, Sakai T, Fujioka S, Mori T, Ohoka Y, Takeda N, Kubo T, Inagaki S. Developmental localization of semaphorin H messenger RNA acting as a collapsing factor on sensory axons in the mouse brain. *Neuroscience* 1999; 93:401-8; PMID:10430503; [http://dx.doi.org/10.1016/S0306-4522\(99\)00134-7](http://dx.doi.org/10.1016/S0306-4522(99)00134-7) 940
- [103] Casazza A, Finisguerra V, Capparuccia L, Camperi A, Swiercz JM, Rizzolio S, Rolny C, Christensen C, Bertotti A, Sarotto I, et al. Sema3E-Plexin D1 signaling drives human cancer cell invasiveness and metastatic

- spreading in mice. *J Clin Invest* 2010; 120:2684-98; PMID:20664171; <http://dx.doi.org/10.1172/JCI42118>
- 950 [104] Taniguchi M, Masuda T, Fukaya M, Kataoka H, Mishina M, Yaginuma H, Watanabe M, Shimizu T. Identification and characterization of a novel member of murine semaphorin family. *Genes Cells* 2005; 10:785-92; PMID:16098142; <http://dx.doi.org/10.1111/j.1365-2443.2005.00877.x>
- 955 [105] Sahay A, Molliver ME, Ginty DD, Kolodkin AL. Semaphorin 3F is critical for development of limbic system circuitry and is required in neurons for selective CNS axon guidance events. *J Neurosci* 2003; 23:6671-80; PMID:12890759
- 960 [106] Fantin A, Vieira JM, Plein A, Denti L, Fruttiger M, Pollard JW, Ruhrberg C. NRP1 acts cell autonomously in endothelium to promote tip cell function during sprouting angiogenesis. *Blood* 2013; 121:2352-62; PMID:23315162; <http://dx.doi.org/10.1182/blood-2012-05-424713>
- 965 [107] Giger RJ, Cloutier JF, Sahay A, Prinjha RK, Levengood DV, Moore SE, Pickering S, Simmons D, Rastan S, Walsh FS, et al. Neuropilin-2 is required in vivo for selective axon guidance responses to secreted semaphorins. *Neuron* 2000; 25:29-41; PMID:10707970; [http://dx.doi.org/10.1016/S0896-6273\(00\)80869-7](http://dx.doi.org/10.1016/S0896-6273(00)80869-7)
- 970 [108] Yuan L, Moyon D, Pardanaud L, Breant C, Karkkainen MJ, Alitalo K, Eichmann A. Abnormal lymphatic vessel development in neuropilin 2 mutant mice. *Development* 2002; 129:4797-806; PMID:12361971
- 975 [109] Takashima S, Kitakaze M, Asakura M, Asanuma H, Sanada S, Tashiro F, Niwa H, Miyazaki Ji J, Hirota S, Kitamura Y, et al. Targeting of both mouse neuropilin-1 and neuropilin-2 genes severely impairs developmental yolk sac and embryonic angiogenesis. *Proc Natl Acad Sci U S A* 2002; 99:3657-62; PMID:11891274; <http://dx.doi.org/10.1073/pnas.022017899>
- 980 [110] Bouvrée K, Brunet I, Del Toro R, Gordon E, Prahst C, Cristofaro B, Mathivet T, Xu Y, Soueid J, Fortuna V, et al. Semaphorin3A, Neuropilin-1, and PlexinA1 are required for lymphatic valve formation. *Circ Res* 2012; 111:437-45; <http://dx.doi.org/10.1161/CIRCRESAHA.112.269316>
- 985 [111] Takegahara N, Takamatsu H, Toyofuku T, Tsujimura T, Okuno T, Yukawa K, Mizui M, Yamamoto M, Prasad DV, Suzuki K, et al. Plexin-A1 and its interaction with DAP12 in immune responses and bone homeostasis. *Nat Cell Biol* 2006; 8:615-22; PMID:16715077; <http://dx.doi.org/10.1038/ncb1416>
- 990 [112] Suto F, Tsuboi M, Kamiya H, Mizuno H, Kiyama Y, Komai S, Shimizu M, Sanbo M, Yagi T, Hiromi Y, et al. Interactions between plexin-A2, plexin-A4, and semaphorin 6A control lamina-restricted projection of hippocampal mossy fibers. *Neuron* 2007; 53:535-47; PMID:17296555; <http://dx.doi.org/10.1016/j.neuron.2007.01.028>
- 995 [113] Toyofuku T, Yoshida J, Sugimoto T, Yamamoto M, Makino N, Takamatsu H, Takegahara N, Suto F, Hori M, Fujisawa H, et al. Repulsive and attractive semaphorins cooperate to direct the navigation of cardiac neural crest cells. *Dev Biol* 2008; 321:251-62; PMID:18625214; <http://dx.doi.org/10.1016/j.ydbio.2008.06.028>
- 1000
- 1005